$ABCL
AbCellera Biologics Inc. Stock $abcl

$abcl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000170305723000008 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$10.06M	$12.19M
YoY Change	-78.1%	-96.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.36M	$18.91M
YoY Change	10.44%	13.63%
% of Gross Profit
Research & Development	$36.47M	$52.65M
YoY Change	36.68%	99.68%
% of Gross Profit
Depreciation & Amortization	$5.610M	$2.900M
YoY Change	14.56%	107.14%
% of Gross Profit
Operating Expenses	$61.45M	$77.07M
YoY Change	13.13%	-15.9%
Operating Profit	-$51.39M	-$64.87M
YoY Change	512.07%	-128.84%
Interest Expense	$10.78M	$9.759M
YoY Change		713.25%
% of Operating Profit
Other Income/Expense, Net	$2.606M	$16.73M
YoY Change	72.58%	185.48%
Pretax Income	-$38.00M	-$48.15M
YoY Change	451.9%	-120.86%
Income Tax	-$7.476M	-$8.038M
% Of Pretax Income
Net Earnings	-$30.53M	-$40.11M
YoY Change	349.93%	-123.79%
Net Earnings / Revenue	-303.58%	-328.99%
Basic Earnings Per Share	-$0.11	-$0.14
Diluted Earnings Per Share	-$0.11	-$0.14
COMMON SHARES
Basic Shares Outstanding	288.7M shares	287.7M
Diluted Shares Outstanding	288.9M shares	287.8M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$179.7M	$193.0M
YoY Change	-77.26%	-64.63%
Cash & Equivalents	$179.7M	$193.0M
Short-Term Investments	$615.9M	$603.5M
Other Short-Term Assets	$47.36M	$99.16M
YoY Change	-31.25%	242.84%
Inventory	$1.447M	$1.447M
Prepaid Expenses
Receivables	$661.6M	$623.5M
Other Receivables	$40.55M	$79.57M
Total Short-Term Assets	$930.7M	$940.7M
YoY Change	-18.64%	-19.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$259.6M	$233.2M
YoY Change	74.05%	91.06%
Goodwill	$47.81M	$47.81M
YoY Change		0.0%
Intangibles	$126.7M	$128.8M
YoY Change		-11.62%
Long-Term Investments	$58.79M	$57.58M
YoY Change	-10.68%	-2.21%
Other Assets	$113.4M	$89.85M
YoY Change	158.76%	107.07%
Total Long-Term Assets	$606.4M	$557.3M
YoY Change	34.81%	33.35%
TOTAL ASSETS
Total Short-Term Assets	$930.7M	$940.7M
Total Long-Term Assets	$606.4M	$557.3M
Total Assets	$1.537B	$1.498B
YoY Change	-3.55%	-5.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.03M	$17.57M
YoY Change	103.87%	69.72%
Accrued Expenses	$5.953M	$5.868M
YoY Change	47.97%
Deferred Revenue	$8.542M	$11.81M
YoY Change		28.48%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$118.9M	$89.59M
YoY Change	-46.23%	-58.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$190.3M	$2.962M
YoY Change	52.0%	-13.64%
Total Long-Term Liabilities	$190.3M	$199.8M
YoY Change	52.0%	16.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$118.9M	$89.59M
Total Long-Term Liabilities	$190.3M	$199.8M
Total Liabilities	$342.3M	$289.4M
YoY Change	-10.13%	-24.78%
SHAREHOLDERS EQUITY
Retained Earnings	$355.5M	$386.1M
YoY Change		-11.5%
Common Stock	$841.2M	$824.4M
YoY Change		7.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.195B	$1.209B
YoY Change
Total Liabilities & Shareholders Equity	$1.537B	$1.498B
YoY Change	-3.55%	-5.93%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$30.53M	-$40.11M
YoY Change	349.93%	-123.79%
Depreciation, Depletion And Amortization	$5.610M	$2.900M
YoY Change	14.56%	107.14%
Cash From Operating Activities	$19.90M	-$44.06M
YoY Change	-92.71%	-143.97%
INVESTING ACTIVITIES
Capital Expenditures	$27.20M	$14.98M
YoY Change	-186.84%	3.37%
Acquisitions
YoY Change
Other Investing Activities	-$7.189M	-$134.6M
YoY Change	-274.28%	1033.59%
Cash From Investing Activities	-$34.39M	-$149.6M
YoY Change	26.45%	467.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	419.0K	-$458.0K
YoY Change	-64.28%	-85.37%
NET CHANGE
Cash From Operating Activities	19.90M	-$44.06M
Cash From Investing Activities	-34.39M	-$149.6M
Cash From Financing Activities	419.0K	-$458.0K
Net Change In Cash	-14.07M	-$194.3M
YoY Change	-105.7%	-375.61%
FREE CASH FLOW
Cash From Operating Activities	$19.90M	-$44.06M
Capital Expenditures	$27.20M	$14.98M
Free Cash Flow	-$7.298M	-$59.05M
YoY Change	-102.4%	-168.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001703057
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39781
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AbCellera Biologics Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2215 Yukon Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V5Y 0A1
CY2023Q1	dei	City Area Code CityAreaCode	604
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	559-9005
CY2023Q1	dei	Security12b Title Security12bTitle	Common shares, no par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ABCL
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	288728094	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386535000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193017000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	499950000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	603478000	usd
CY2022Q4	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	886485000	usd
CY2023Q1	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	796495000	usd
CY2022Q4	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	38593000	usd
CY2023Q1	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	20003000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	25000000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	25000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	75413000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	99155000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1025491000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	940653000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	217255000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	233187000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131502000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	128845000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	47806000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	47806000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	72522000	usd
CY2023Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	57583000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46331000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	89845000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	515416000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	557266000	usd
CY2022Q4	us-gaap	Assets Assets	1540907000	usd
CY2023Q1	us-gaap	Assets Assets	1497919000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	33150000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	31814000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	44211000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	42876000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	19347000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3094000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21612000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11807000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118320000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	89591000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76675000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	77265000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	19516000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25416000	usd
CY2022Q4	abcl	Deferred Grants Funding Noncurrent DeferredGrantsFundingNoncurrent	40801000	usd
CY2023Q1	abcl	Deferred Grants Funding Noncurrent DeferredGrantsFundingNoncurrent	45026000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16054000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	15733000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33178000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33426000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3086000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2962000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	189310000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	199828000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	307630000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	289419000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	286851595	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	286851595	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	288426514	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	288426514	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	734365000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	742816000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74118000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81630000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1391000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2021000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	426185000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	386075000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1208500000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1540907000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1497919000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	316581000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12192000	usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	44637000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26366000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52647000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2370000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3771000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14268000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15134000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3990000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5514000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	91631000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	77066000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	224950000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-64874000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	665000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	9759000	usd
CY2022Q1	abcl	Grants And Incentives GrantsAndIncentives	5194000	usd
CY2023Q1	abcl	Grants And Incentives GrantsAndIncentives	3374000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3593000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5859000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16726000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	230809000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48148000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62236000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8038000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	168573000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40110000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-630000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	169080000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40740000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	283895020	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	287767136	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	311482017	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	287767136	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	489000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15474000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-630000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40110000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1208500000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1025733000	usd
CY2022Q1	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	403000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12291000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	168573000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1207507000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	168573000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-40110000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1391000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2858000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2606000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2656000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	976000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1606000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12291000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	15474000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	592000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3634000	usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	8751000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-7915000	usd
CY2022Q1	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	167914000	usd
CY2023Q1	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-9260000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	69965000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-12614000	usd
CY2022Q1	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	751000	usd
CY2023Q1	abcl	Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable	-5778000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	941000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3905000	usd
CY2022Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	22857000	usd
CY2023Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-16253000	usd
CY2022Q1	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-4682000	usd
CY2023Q1	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-4525000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7557000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6063000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	100219000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44063000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14495000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14984000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	51774000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	360752000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	57294000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	262638000	usd
CY2022Q1	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	2596000	usd
CY2023Q1	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	2693000	usd
CY2022Q1	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	11657000	usd
CY2023Q1	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	34735000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	8335000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4469000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26371000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-149609000	usd
CY2022Q1	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	5072000	usd
CY2023Q1	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	948000	usd
CY2022Q1	abcl	Proceeds From Debt And Exercise Of Stock Options ProceedsFromDebtAndExerciseOfStockOptions	1941000	usd
CY2023Q1	abcl	Proceeds From Debt And Exercise Of Stock Options ProceedsFromDebtAndExerciseOfStockOptions	490000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3131000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-458000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-204000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-213000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70513000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-194343000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	501142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414650000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	571655000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	220307000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	937000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	570718000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218017000	usd
CY2022Q1	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	2353000	usd
CY2023Q1	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	8918000	usd
CY2022Q1	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	658000	usd
CY2023Q1	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	2124000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of operationsAbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div>
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	168573000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40110000	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	283895020	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	287767136	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	168573000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-40110000	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	283895020	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	287767136	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	27586997	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	311482017	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	287767136	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2974052	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50844425	shares
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	235730000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	254520000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18475000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21333000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	217255000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	233187000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25600000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	38900000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1400000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2900000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5583000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	154583000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	25738000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	128845000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10599000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4241000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4241000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4241000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4241000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27563000	usd
CY2023Q1	abcl	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	64817000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	79566000	usd
CY2022Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	9064000	usd
CY2023Q1	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	18142000	usd
CY2022Q4	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1532000	usd
CY2023Q1	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1447000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	75413000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	99155000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14828000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17569000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5868000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6454000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1792000	usd
CY2022Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	6285000	usd
CY2023Q1	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	6585000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	33150000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	31814000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12291000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15474000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	34954000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	35861000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41128000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37223000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2700000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4800000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	29700000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	18500000	usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	44600000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	0	usd

Files In Submission

Name	View Source	Status
abcl-20230331_cal.xml	Edgar Link	unprocessable
0001703057-23-000008-index-headers.html	Edgar Link	pending
0001703057-23-000008-index.html	Edgar Link	pending
0001703057-23-000008.txt	Edgar Link	pending
0001703057-23-000008-xbrl.zip	Edgar Link	pending
abcl-20230331.htm	Edgar Link	pending
abcl-20230331.xsd	Edgar Link	pending
abcl-20230331xexx311.htm	Edgar Link	pending
abcl-20230331xexx312.htm	Edgar Link	pending
abcl-20230331xexx321.htm	Edgar Link	pending
abcl-20230331xexx322.htm	Edgar Link	pending
abcl-20230331_g1.gif	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
abcl-20230331_def.xml	Edgar Link	unprocessable
abcl-20230331_lab.xml	Edgar Link	unprocessable
abcl-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abcl-20230331_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABCL
AbCellera Biologics Inc. Stock $abcl

2023 Q2 Form 10-Q Financial Statement

#000170305723000008 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL AbCellera Biologics Inc. Stock $abcl

2023 Q2 Form 10-Q Financial Statement

#000170305723000008 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL
AbCellera Biologics Inc. Stock $abcl